Article

Subclinical hypopituitarism

Endocrinology Division, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Departamento de Medicina, Universidad de Santiago de Compostela, Travesía da Choupana s/n. 15706 Santiago de Compostela, La Coruña, Spain.
Best Practice & Research: Clinical Endocrinology & Metabolism (Impact Factor: 4.6). 08/2012; 26(4):461-9. DOI: 10.1016/j.beem.2011.10.007
Source: PubMed

ABSTRACT

The presence of subclinical or minor pituitary hormone deficiencies could be recognised in clinical practice and might represent intermediate situations among normal pituitary hormone secretion and clinical hypopituitarism. However, this entity has not been correctly identified and associated clinical impairment and even more, long-term consequences regarding to morbidity and mortality, strongly related to clinical hypopituitarism, has not been correctly settled. Furthermore, best test or methods for diagnosis and the cut off to define these intermediate situates are also unknown. With this purpose, long-term controlled studies are needed to define correctly this entity, the appropriate methods for diagnosis and the potential benefits of substitutive hormone therapy in detected cases. The present review will focus on the available evidence concerning the prevalence, clinical features and diagnosis of subclinical hypopituitarism.

Download full-text

Full-text

Available from: Ignacio Bernabeu
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The panhypopituitarism is a rare endocrine system disease; the clinical presentation of a panhypopituitarism patient can vary from asymptomatic or subclinical cases to life-threatening myxedema coma. Case report: Our patient is a 55 years old woman who was presented to emergency department with chief complains of weakness. After necessary workup, panhypopituitarism was diagnosed. Discussion: There are different diagnoses for weakness. In patients with vague complaints such as weakness, we should take their history carefully and perform clinical examinations to reach a definitive diagnosis.
    Full-text · Article · Dec 2013 · Open Access Emergency Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: ContextDiagnosis of secondary adrenal insufficiency and GH deficiency requires evaluation by dynamic stimulation tests in most cases. Although insulin tolerance test (ITT) is accepted as the gold-standard test for the evaluation of both hypothalamo-pituitary-adrenal (HPA) and (GH)-IGF-1 axes, the test is cumbersome. In clinical practice, low-dose adrenocorticotrophic hormone (ACTH) stimulation test is a sensitive, safe and easily applicable alternative to ITT. Although it takes more time, glucagon stimulation test (GST) is also a good alternative to ITT and can evaluate both axes. Objective The primary aim of this study was to compare the ITT, low-dose ACTH and GSTs in the evaluation of HPA and GH-IGF-1 axes in patients with pituitary disorders and to evaluate the repeatability of all three tests. DesignITT, low-dose ACTH and GSTs were performed in all 129 patients, and the tests were repeated in 66 of these patients. SettingErciyes University Medical School, Department of Endocrinology. Patients or Other ParticipantsOne hundred and twenty-nine adult patients (76 women, 53 men) with pituitary disorder were included in the study. Main Outcome Measure(s)The cortisol and GH responses of patients to dynamic tests. ResultsPeak cortisol levels obtained during ITT were significantly lower than the values obtained during both low-dose ACTH and GSTs. Peak cortisol levels obtained during the GST were lower than those found during the low dose ACTH stimulation test. Peak GH responses were found to be higher in GST than in ITT. All three tests had good reproducibility. Conclusions Any of 3 tests can be used in the evaluation of the HPA axis and either GST or the ITT can be used in the evaluation of the GH-IGF-1 axis but cut-off levels for the insufficiency of HPA or GH-IGF-1 axis should be individualized for each test.
    No preview · Article · Jun 2014 · Clinical Endocrinology